camostat has been researched along with Bright Disease in 3 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated." | 9.11 | Effect of oral camostat mesilate on hematuria and/or proteinuria in children. ( Asami, T; Tomisawa, S; Uchiyama, M, 2004) |
| "Camostat mesilate, a developed derivative of gabexate mesilate for oral use, was administered in a daily dose of 600 mg for 4 weeks to 17 patients with heavy proteinuria due to various nephropathies." | 7.67 | Effect of camostat mesilate on heavy proteinuria in various nephropathies. ( Futaki, G; Hotta, O; Kurosawa, K; Matsubara, M; Suzuki, K; Taguma, Y, 1989) |
| "The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated." | 5.11 | Effect of oral camostat mesilate on hematuria and/or proteinuria in children. ( Asami, T; Tomisawa, S; Uchiyama, M, 2004) |
| "Effect of serine protease inhibitor Camostat Mesilate (Foipan) on primary glomerulonephritis and it's mechanism were evaluated." | 3.68 | [Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect]. ( Fukushima, M; Haramoto, T; Kumagai, I; Makino, H; Murakami, K; Ogura, T; Onbe, T; Ota, Z; Wada, J, 1991) |
| "Camostat mesilate, a developed derivative of gabexate mesilate for oral use, was administered in a daily dose of 600 mg for 4 weeks to 17 patients with heavy proteinuria due to various nephropathies." | 3.67 | Effect of camostat mesilate on heavy proteinuria in various nephropathies. ( Futaki, G; Hotta, O; Kurosawa, K; Matsubara, M; Suzuki, K; Taguma, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asami, T | 1 |
| Tomisawa, S | 1 |
| Uchiyama, M | 1 |
| Onbe, T | 1 |
| Makino, H | 1 |
| Haramoto, T | 1 |
| Wada, J | 1 |
| Ogura, T | 1 |
| Kumagai, I | 1 |
| Murakami, K | 1 |
| Fukushima, M | 1 |
| Ota, Z | 1 |
| Matsubara, M | 1 |
| Taguma, Y | 1 |
| Kurosawa, K | 1 |
| Hotta, O | 1 |
| Suzuki, K | 1 |
| Futaki, G | 1 |
1 trial available for camostat and Bright Disease
| Article | Year |
|---|---|
Effect of oral camostat mesilate on hematuria and/or proteinuria in children.
Topics: Administration, Oral; Adolescent; Biopsy; Child; Child, Preschool; Esters; Female; Follow-Up Studies | 2004 |
2 other studies available for camostat and Bright Disease
| Article | Year |
|---|---|
[Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Urea Nitrogen; Complement System Proteins; Creatin | 1991 |
Effect of camostat mesilate on heavy proteinuria in various nephropathies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Esters; Female; Gabexate; Glomerulonephritis; Glycosu | 1989 |